NCT01345006View on ClinicalTrials.gov

Sub-retinal Transplantation of hESC Derived RPE(MA09-hRPE)Cells in Patients With Stargardt's Macular Dystrophy

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

June 16, 2011

Primary Completion Date

August 10, 2015

Study Completion Date

August 10, 2015

Conditions
Stargardt's Macular Dystrophy
Interventions
BIOLOGICAL

MA09-hRPE

"Cohort 1 50,000 cells~Cohort 2 100,000 cells~Cohort 2a Better Vision 100,000 cells~Cohort 3 150,000 cells~Cohort 4 200,000 cells"

Trial Locations (3)

19107

Wills Eye Institute-Mid Atlantic Retina, Philadelphia

33136

Bascom Palmer Eye institute, Miami

90095

Jules Stein Eye Institute, UCLA School of Medicine, Los Angeles

All Listed Sponsors
lead

Astellas Institute for Regenerative Medicine

INDUSTRY

NCT01345006 - Sub-retinal Transplantation of hESC Derived RPE(MA09-hRPE)Cells in Patients With Stargardt's Macular Dystrophy | Biotech Hunter | Biotech Hunter